Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

Published:2012-08-02 Issue:5 Volume:367 Page:435-444
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Mehta Rita S.,Barlow William E.,Albain Kathy S.,Vandenberg Ted A.,Dakhil Shaker R.,Tirumali Nagendra R.,Lew Danika L.,Hayes Daniel F.,Gralow Julie R.,Livingston Robert B.,Hortobagyi Gabriel N.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1201622

Cited by 345 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study;Journal of Clinical Oncology;2024-09-06

2. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2‐ metastatic breast cancer: A single center real‐world study in China;Cancer Medicine;2024-05

3. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination;JAMA Oncology;2024-03-01

4. A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer;BMC Medicine;2024-01-12

5. Deregulated transcription factors in the emerging cancer hallmarks;Seminars in Cancer Biology;2024-01